Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as VIR-7831 (sotrovimab)
VIR-7831 · 1 trial · 1 indication
COVID-19 progression defined as hospitalization \>24 hours or death
| Arm | Type | Description |
|---|---|---|
| VIR-7831 (Sotrovimab) | EXPERIMENTAL | Participants received 500 mg sotrovimab administered intravenously (IV) |
| Placebo | PLACEBO_COMPARATOR | Participants received placebo administered intravenously (IV) |
| Name | Type | Description |
|---|---|---|
| VIR-7831 (sotrovimab) | BIOLOGICAL | VIR-7831 (sotrovimab) given by intravenous infusion (single dose) |
| Placebo | DRUG | Sterile normal saline (0.9% NaCl) given by intravenous infusion (single dose) |
Inclusion Criteria: * Participant must be aged 18 years or older AND at high risk of progression of COVID-19 or ≥ 55 years old * Participants must have a positive SARS-CoV-2 test result and oxygen saturation ≥94% on room air and have COVID-19 symptoms and be less than or equal to 5 days from onset ...
VIR-7831 is an investigational monoclonal antibody developed by Vir Biotechnology, Inc. (ticker: VIR) for the treatment of COVID-19. It is designed to target the SARS-CoV-2 virus. VIR-7831 is also known as sotrovimab. It is currently in Phase 2 clinical development and has been studied in a completed Phase 2 trial.
VIR-7831 is being developed for the treatment of COVID-19, the disease caused by the SARS-CoV-2 virus. It is intended for early treatment of COVID-19 in outpatients, as studied in a Phase 2 clinical trial. The drug is investigational and has not been approved for any indication.
VIR-7831 targets the SARS-CoV-2 virus. As a monoclonal antibody, it is designed to bind to the virus and potentially neutralize it. This mechanism is intended to interfere with the virus's ability to infect cells and cause COVID-19.
VIR-7831 is being developed by Vir Biotechnology, Inc., which trades under the ticker symbol VIR. The company is responsible for the clinical development of this monoclonal antibody for COVID-19.
VIR-7831 is in Phase 2 clinical development. It has completed one Phase 2 trial, NCT04545060, which enrolled 1057 participants. The drug is investigational and has not been approved by the FDA or any regulatory agency for any indication.
VIR-7831 has been studied in a Phase 2 clinical trial, NCT04545060, titled "VIR-7831 for the Early Treatment of COVID-19 in Outpatients." This trial was completed and enrolled 1057 participants across the United States, Austria, Brazil, Canada, Peru, Spain, and the United Kingdom. It was randomized, double-blind, and placebo-controlled.
Yes, VIR-7831 is also known as sotrovimab. Both names refer to the same investigational monoclonal antibody developed by Vir Biotechnology for COVID-19. Sotrovimab is the international nonproprietary name for VIR-7831.